Guardant Health Valuation

GH Stock  USD 97.97  2.70  2.83%   
At this time, the firm appears to be undervalued. Guardant Health retains a regular Real Value of $115.03 per share. The prevalent price of the firm is $97.97. Our model calculates the value of Guardant Health from evaluating the firm fundamentals such as return on equity of -45.84, and Return On Asset of -0.16 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Guardant Health's valuation include:
Price Book
55.6696
Enterprise Value
8.4 B
Enterprise Value Ebitda
(5.40)
Price Sales
12.9567
Enterprise Value Revenue
10.0977
Undervalued
Today
97.97
Please note that Guardant Health's price fluctuation is very steady at this time. Calculation of the real value of Guardant Health is based on 3 months time horizon. Increasing Guardant Health's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Guardant Health is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Guardant Stock. However, Guardant Health's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  97.97 Real  115.03 Target  132.57 Hype  98.34 Naive  98.34
The intrinsic value of Guardant Health's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Guardant Health's stock price.
115.03
Real Value
117.95
Upside
Estimating the potential upside or downside of Guardant Health helps investors to forecast how Guardant stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Guardant Health more accurately as focusing exclusively on Guardant Health's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-0.8-0.47-0.29
Details
Hype
Prediction
LowEstimatedHigh
95.4298.34101.26
Details
Naive
Forecast
LowNext ValueHigh
95.4298.34101.26
Details
24 Analysts
Consensus
LowTarget PriceHigh
120.63132.57147.15
Details
When choosing an evaluation method for Guardant Health, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.

Guardant Health Cash

428.31 Million

Guardant Revenue by Product

Guardant Health Total Value Analysis

Guardant Health is currently forecasted to have takeover value of 8.37 B with market capitalization of 12.72 B, debt of 1.68 B, and cash on hands of 853.69 M. Please note that takeover value may be misleading and is a subject to accounting mistakes. We encourage investors to methodically examine all of the Guardant Health fundamentals before making investment evaluation based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
8.37 B
12.72 B
1.68 B
853.69 M

Guardant Health Investor Information

About 96.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.22. Guardant Health had not issued any dividends in recent years. Guardant Health may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.

Guardant Health Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Guardant Health has an asset utilization ratio of 48.77 percent. This signifies that the Company is making $0.49 for each dollar of assets. An increasing asset utilization means that Guardant Health is more efficient with each dollar of assets it utilizes for everyday operations.
 
Covid
 
Interest Hikes

Guardant Health Profitability Analysis

Considering the key profitability indicators obtained from Guardant Health's historical financial statements, Guardant Health may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Guardant Health's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2016-12-31
Previous Quarter
-92.7 M
Current Value
-128.5 M
Quarterly Volatility
54 M
 
Covid
 
Interest Hikes
The Guardant Health's current Gross Profit is estimated to increase to about 664.7 M, while Pretax Profit Margin is projected to decrease to (0.45).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.440.6446
Way Down
Slightly volatile
For Guardant Health profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Guardant Health to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Guardant Health utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Guardant Health's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Guardant Health over time as well as its relative position and ranking within its peers.

Guardant Health Earnings per Share Projection vs Actual

The next projected EPS of Guardant Health is estimated to be -0.4734 with future projections ranging from a low of -0.798 to a high of -0.29. Guardant Health's most recent 12-month trailing earnings per share (EPS TTM) is at -3.22. Please be aware that the consensus of earnings estimates for Guardant Health is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Guardant Health is projected to generate -0.4734 in earnings per share on the 31st of March 2026. Guardant Health earnings estimates show analyst consensus about projected Guardant Health EPS (Earning Per Share). It derives the highest and the lowest estimates based on Guardant Health's historical volatility. Many public companies, such as Guardant Health, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Guardant Health Earnings Estimation Breakdown

The calculation of Guardant Health's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Guardant Health is estimated to be -0.4734 with the future projection ranging from a low of -0.798 to a high of -0.29. Please be aware that this consensus of annual earnings estimates for Guardant Health is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.5
-0.8
Lowest
Expected EPS
-0.4734
-0.29
Highest

Guardant Health Earnings Projection Consensus

Suppose the current estimates of Guardant Health's value are higher than the current market price of the Guardant Health stock. In this case, investors may conclude that Guardant Health is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Guardant Health's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2026Current EPS (TTM)
2461.79%
-0.5
-0.4734
-3.22

Guardant Health Ownership Allocation

The majority of Guardant Health outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Guardant Health to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Guardant Health. Please pay attention to any change in the institutional holdings of Guardant Health as this could imply that something significant has changed or is about to change at the company. On December 1, 2025, Senator Sheldon Whitehouse of US Senate acquired under $15k worth of Guardant Health's common stock.

Guardant Health Profitability Analysis

The company generated the yearly revenue of 982.02 M. Annual Net Loss to common stockholders was (416.28 M) with gross profit of 633.01 M.

About Guardant Health Valuation

An absolute valuation paradigm, as applied to Guardant Stock, attempts to find the value of Guardant Health based on its fundamental and basic technical indicators. By analyzing Guardant Health's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Guardant Health's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Guardant Health. We calculate exposure to Guardant Health's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Guardant Health's related companies.
Last ReportedProjected for Next Year
Gross Profit633 M664.7 M
Pretax Profit Margin(0.43)(0.45)
Operating Profit Margin(0.44)(0.47)
Net Loss(0.42)(0.45)
Gross Profit Margin 0.64  0.44 

Guardant Health Current Valuation Indicators

Valuation refers to the process of determining the present value of Guardant Health and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Guardant we look at many different elements of the entity such as Guardant's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Guardant Health, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Guardant Health's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Guardant Health's worth.

Complementary Tools for Guardant Stock analysis

When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Transaction History
View history of all your transactions and understand their impact on performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios